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Background: Antimicrobial peptides have been the focus of much research over the last decade because of their
effectiveness and broad-spectrum activity against microbial pathogens. These peptides also participate in inflammation
and the innate host defense system by modulating the immune function that promotes immune cell adhesion and
migration as well as the respiratory burst, which makes them even more attractive as therapeutic agents. This has led
to the synthesis of various antimicrobial peptides, including KSL-W (KKVVFWVKFK-NH2), for potential clinical use. Because
this peptide displays antimicrobial activity against bacteria, we sought to determine its antifungal effect on C. albicans.
Growth, hyphal form, biofilm formation, and degradation were thus examined along with EFG1, NRG1, EAP1, HWP1,
and SAP 2-4-5-6 gene expression by quantitative RT-PCR.
Results: This study demonstrates that KSL-W markedly reduced C. albicans growth at both early and late incubation
times. The significant effect of KSL-W on C. albicans growth was observed beginning at 10 μg/ml after 5 h of contact by
reducing C. albicans transition and at 25 μg/ml by completely inhibiting C. albicans transition. Cultured C. albicans under
biofilm-inducing conditions revealed that both KSL-W and amphotericin B significantly decreased biofilm formation at 2,
4, and 6 days of culture. KSL-W also disrupted mature C. albicans biofilms. The effect of KSL-W on C. albicans growth,
transition, and biofilm formation/disruption may thus occur through gene modulation, as the expression of various
genes involved in C. albicans growth, transition and biofilm formation were all downregulated when C. albicans was
treated with KSL-W. The effect was greater when C. albicans was cultured under hyphae-inducing conditions.
Conclusions: These data provide new insight into the efficacy of KSL-W against C. albicans and its potential use as an
antifungal therapy.
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The innate defense system plays a key role in protecting
the host against microorganism-fueled infections such as
candidiasis caused by Candida albicans. C. albicans col-
onizes several body sites, including the oral cavity; how-
ever, as a commensal organism, it causes no apparent
damage or inflammation in the surrounding tissue [1,2].
C. albicans is a polymorphic organism that adheres to
different surfaces in the body and can grow as yeast,
pseudohyphae, and hyphae [3], usually in the form of
biofilm. C. albicans transition, biofilm formation, and* Correspondence: mahmoud.rouabhia@fmd.ulaval.ca
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reproduction in any medium, provided the orpathogenesis are under the control of various genes. The
HWP1 gene encodes the hyphal cell wall protein, which
is a hyphal-specific adhesin that is essential to biofilm
formation [4]. The involvement of HWP1 in C. albicans
adhesion is supported by the EAP1 gene which encodes
a glucan-crosslinked cell wall protein (adhesin Eap1p).
Together, these components mediate C. albicans adhe-
sion to various surfaces, such as epithelial cells and poly-
styrene [5]. Like many other genes, HWP1 and EAP1 are
downstream effectors of EFG1 and NRG1 as transcrip-
tion factors [6,7]. EFG1 mutant strain has been shown to
exhibit defects in growth, biofilm formation, and viru-
lence [8], while NRG1 represses filamentous growth [3].
This occurs through the DNA binding protein Nrg1p in
conjunction with the global transcriptional repressorral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expression represses the expression of a number of
hypha-specific genes, although NRG1 downregulation is
associated with C. albicans filaments [3].
C. albicans virulence is also mediated by proteolytic
enzymes, including secreted aspartyl proteinases (SAPs)
[9,10]. The contribution of SAPs in C. albicans adher-
ence, tissue damage, and evasion of host immune re-
sponses has been reported [9]. SAP2 is crucial to C.
albicans growth in protein-containing media [11]. SAP1
and SAP3 are expressed during phenotypic switching
[12,13], while SAP4, SAP5, and SAP6 are expressed
upon hyphal formation [14], and SAPs 1-6 and 9-10 are
involved in the adhesion mechanism to host cells [15].
To control C. albicans pathogenesis, the host innate
immunity uses small molecules such as proteins and
peptides that display a broad antimicrobial spectrum.
The number of identified potentially antimicrobial pep-
tides is significant and continues to increase [16]. Anti-
microbial peptides often possess common attributes,
such as small size, an overall positive charge, and amphi-
pathicity [17,18]; however, they also fall into a number
of distinctively diverse groups, including α-helical pep-
tides, β-sheet peptides, peptides with mixed α-helical
and β-sheet structures, extended peptides, and peptides
enriched in specific amino acids [16].
In humans, epithelial cells and neutrophils are the most
important cells producing antimicrobial peptides [19,20].
These peptides are most often antibacterial, although anti-
fungal activity has also been reported [16,21]. The major
peptide groups known to date are the histatins, cathelici-
dins, defensins, and lactoferricins [22]. The antimicrobial
activity of these peptides has been reported by different
in vitro and in vivo studies [19,20,22]. Their complex role
as well as their contribution to host defenses may be re-
lated to the functional interrelationship between innate
and adaptive immunity [23,24].
The interest in antimicrobial peptides lies in the pos-
sible resistance of microorganisms to conventional anti-
microbial strategies used against microbial pathogens in
both agriculture and medicine [25,26]. Natural anti-
microbial peptides are necessary in the control of micro-
bial infections. For example, the use of AMPs provided
protection against such microbial pathogens as fungal
pathogens, with no reported effect on the host [27,28].
Based on these promising data, a number of synthetic
AMPs have been designed to overcome microbial infec-
tions [29]. In the pursuit of a novel alternative antifungal
treatment, we developed a synthetic α-helical antimicro-
bial decapeptide, KSL (KKVVFKVKFK), and its analogue
KSL-W (KKVVFWVKFK) [30].
The efficacy of KSL on a wide range of microorgan-
isms has been established [31-33], as well as its ability to
disrupt oral biofilm growth [34]. KSL-W, a recentlysynthesized KSL analogue, was shown to display im-
proved stability in simulated oral and gastric conditions
with in vitro preserved antimicrobial activity [30]. Fur-
thermore, combined with sub-inhibitory concentrations
of benzalkonium chloride, a known cationic surface-
active agent [35], KSL was shown to significantly pro-
mote bacterial biofilm susceptibility. We also recently
demonstrated that KSL-W had a selective effect on C.
albicans growth, while exhibiting no toxic effect on epi-
thelial cells [36].
As this KSL-W analogue displays a wide range of mi-
crobicidal activities, effectively kills bacteria, controls
biofilm formation, and destroys intact biofilms, we hy-
pothesized that KSL-W may also possess antifungal po-
tential. Our goal was thus to investigate the ability of
KSL-W to inhibit C. albicans growth and transition from
blastospore to hyphal form. The action of KSL-W on
biofilm formation/disruption was also assessed. Finally,
we examined the effect of KSL-W on various C. albicans
genes involved in its growth, transition, and virulence.
Results
Antimicrobial peptide KSL-W reduced C. albicans growth
and transition from blastospore to hyphal form
C. albicans cultures were incubated with KSL-W for 5,
10, and 15 h to determine whether this antimicrobial
peptide had any adverse effect on C. albicans growth. As
shown in Figure 1, KSL-W significantly reduced C. albi-
cans proliferation. After 5 h of contact with KSL-W, the
growth inhibition of C. albicans was between 30 and
80%, depending on the concentration of KSL-W used
(Figure 1A). After 10 h of contact with KSL-W, growth
inhibition was significant, beginning at 25 μg/ml
(Figure 1B). At later culture periods, C. albicans growth
continued to be significantly affected by the presence of
KSL-W (Figure 1C). Indeed, with 25 μg/ml of KSL-W,
C. albicans growth was almost half that in the controls
(non-treated C. albicans cultures), and with 100 μg/ml
of KSL-W, C. albicans growth was reduced by almost
60%. It is interesting to note that KSL-W in as low as
25 μg/ml was effective at both the early and late culture
periods.
As KSL-W contributed to C. albicans growth inhib-
ition, we hypothesized that it would also downregulate
C. albicans transition from yeast form to hyphal pheno-
type. Yeast cultures supplemented with 10% FBS and the
KSL-W peptide were maintained for various incubation
periods. As shown in Figure 2, germ tube formation was
inhibited as early as 4 h following exposure to the pep-
tide, compared to that in the cultures incubated in the
absence of KSL-W. Of interest is the elevated number of
C. albicans hyphal forms in the negative control culture
(no KSL-W or amphotericin B) compared to the low
number in the presence of KSL-W. The effect of this
Figure 1 KSL-W inhibited C. albicans growth. The yeast was
cultured in Sabouraud supplemented medium with or without KSL-
W at various concentrations. The cultures were maintained for 5, 10,
and 15 h at 37°C, after which time an MTT assay was performed for
each culture condition. The growth was plotted as means ± SD of
the absorbance at 550 nm. (A) C. albicans growth with KSL-W for
5 h; (B) C. albicans growth with KSL-W for 10 h; and (C) C. albicans
growth with KSL-W for 15 h. The levels of significance for C. albicans
growth in the presence or not of KSL-W or amphotericin B (10 μg/
ml) were considered significant at P < 0 · 05.
Theberge et al. BMC Microbiology 2013, 13:246 Page 3 of 14
http://www.biomedcentral.com/1471-2180/13/246antimicrobial peptide on C. albicans transition was also
dose-dependent: at 1 μg/ml, a significant number of hy-
phal forms remained, and at only 5 μg/ml of KSL-W, C.
albicans transition was completely inhibited (Figure 2).
Semi-quantitative analyses using inverted microscope ob-
servations to estimate the hyphal forms confirmed the
inhibited C. albicans transition when treated with KSL-W
(Table 1). The density of the hyphae was reduced as early
as 4 h of contact with 5 μg/ml of KSL-W. This effect was
further supported when C. albicans was placed in contact
with KSL-W for 8 h (Table 1), thus confirming that KSL-W
downregulated C. albicans growth and transition.KSL-W reduced C. albicans biofilm formation
As KSL-W contributed to reducing C. albicans growth
and transition, we sought to determine whether it also
displayed inhibitory activity against C. albicans biofilm
formation. Using a biofilm-promoting scaffold, SEM
analyses, and an XTT assay, we were able to demon-
strate the inhibitory effect of KSL-W on biofilm forma-
tion (Figure 3). SEM analyses revealed a significant
density of C. albicans in the untreated culture, compared
to a lower density in the scaffold in the presence of KSL-W
(1 and 25 μg/ml) after 4 days of culture. The de-
creases obtained with the KSL-W, particularly at 25 μg/ml
(Figure 3), were comparable to that obtained with
amphotericin B at 10 μg/ml. To confirm these observa-
tions, we performed quantitative analyses using the XTT
assay. Figure 4A shows that after 2 days of culture, KSL-W
was able to inhibit biofilm formation. This inhibitory
effect was observed beginning at 25 μg/ml of KSL-W. At
concentrations of 50, 75, and 100 μg/ml of KSL-W, the
inhibition of C. albicans biofilm formation was compar-
able to that caused by amphotericin B at 10 μg/ml. Similar
results were obtained after 4 days (Figure 4B) and 6 days
(Figure 4C) of culture for biofilm formation with a persist-
ent inhibitory effect of KSL-W on C. albicans biofilm
formation.
KSL-W disrupted mature C. albicans biofilms
After 6 days of incubation in glucose-rich Sabouraud
medium, scaffolds seeded with C. albicans strain SC5314
produced mature biofilms displaying highly dense popu-
lations of Candida cells (Figure 5). Significant reductions
and disruptions of the pre-formed Candida biofilms
were observed when the reference antifungal agent
(amphotericin B, 10 μg/ml) was added to the mature
biofilms upon further incubation up to 6 days. Similarly,
antimicrobial peptide KSL-W at 75 and 100 μg/ml also
reduced C. albicans density in the biofilms. The ob-
served reduction was noticed with KSL-W concentra-
tions ranging from 25 to 100 μg/ml. Indeed, when
quantitatively investigated by XTT reduction assay, the
KSL-W-treated biofilms rendered a significantly lower
number of cells, as reflected by the lower absorbance
readings, than did the untreated control. This effect was
observed after 2, 4, and 6 days of treatment with ampho-
tericin B. Furthermore, the effect of KSL-W on the ma-
ture C. albicans biofilm was comparable to that obtained
with amphotericin B (Figure 6).
KSL-W modulated the expression of various C. albicans
genes
Based on the data showing that KSL-W reduced
C. albicans proliferation, transition, and biofilm forma-
tion, we sought to determine the involvement, if any, of
gene regulation. For this purpose, we first investigated the
Figure 2 KSL-W inhibited C. albicans yeast-to-hyphae transition. C. albicans was cultured in Sabouraud medium containing 10% fetal bovine
serum with or without KSL-W at various concentrations and was maintained for 4 and 8 h at 37°C. After each time point, the cultures were observed
under an inverted microscope and photographed. Representative photos of the morphological changes after 4 h of culture are presented.
Table 1 Estimation of hyphae forms in the C. albicans
culture
Active molecules Concentration
(μg/mL)
Transition
at 4 h
Transition
at 8 h
Negative control 0 ++ ++
KSL-W 1 ++ ++
5 - -
10 - -
15 - -
25 - -
100 - -
Amphotericin B 1 - -
This Table depicts the presence of hyphae following 4 and 8 h treatments
of C. albicans with and without KSL-W or amphotericin B. (–) refers to the
absence hyphae form, and (++) refers to the presence high number of hyphae
forms. These data were estimated after evaluation over 20 fields from each
culture condition, by two independent and blinded examiners.
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C. albicans genes when cultured under normal non-
hyphae-inducing conditions. The data in Table 2 indicate
that the HWP1 gene was significantly downregulated fol-
lowing exposure of the C. albicans to KSL-W for 6 h. This
downregulation was comparable to that observed in the
amphotericin B treatment. Similarly, SAPs 2, 4, 5, and 6
were significantly downregulated by KSL-W treatment
after 6 h (Table 2). This effect was observed with both low
and high concentrations of KSL-W. Furthermore, the
EAP1 gene, which encodes a glycosylphosphatidylinositol-
anchored, glucan-crosslinked cell wall protein in both ad-
hesion and biofilm formation in vitro and in vivo, was also
affected by the KSL-W treatment. Moreover, the expres-
sion of this gene was downregulated by KSL-W, yet was
upregulated (up to 5-fold) by amphotericin B.
Two other genes involved in regulating C. albicans
morphogenesis, namely, EFG1 and NRG1, are known to
Figure 3 Scanning electron microscope analyses of the biofilm formation. C. albicans was cultured in Sabouraud medium with or without
KSL-W at various concentrations for 4 days in a porous 3D collagen scaffold. Cultures in the presence of amphotericin B (10 μg/ml) were used as
the positive controls. Following incubation, the samples were prepared as described in the Methods section and were observed under a scanning
electron microscope. Negative control refers to the non-seeded scaffolds.
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creased both EFG1 and NRG1 mRNA expression, with
twice as much expression for NRG1 than for EFG1
(Table 3), while KSL-W induced a less significant in-
crease of EFG1 and NRG1 mRNA expression. Of interest
is that a low KSL-W concentration (25 μg/ml) induced
greater gene expression (Table 3).
In a second set of experiments, C. albicans was cul-
tured under hyphae-inducing conditions (fetal calf
serum-enriched medium with incubation at 37°C) in the
presence or not of KSL-W, after which time gene ex-
pression/repression was investigated. The data in Table 4
reveal that similar to the results obtained with
amphotericin-B, the HWP1 gene was significantly (p <
0.0001) downregulated when C. albicans was exposed toKSL-W for 3 h, confirming the results obtained under
non-hyphae growth conditions.
SAP genes were also modulated by KSL-W treatment.
Table 4 shows that after 3 h of exposure, SAPs 2, 4, 5,
and 6 were significantly (p < 0.05) downregulated by the
KSL-W treatment. In contrast, with amphotericin-B, a sig-
nificant (p < 0.05) increase of SAPs 2, 4, and 6 and a de-
crease of SAP5 was observed. It is interesting to note the
opposite modulatory effects of KSL-W and amphotericin-
B on SAP gene expression. After 6 h of treatment with
KSL-W, a significant decrease of each tested SAP gene
was observed in the exposed C. albicans, whereas after
treatment with amphotericin-B, these same SAP genes in-
creased, thus confirming the antagonistic behavior of
KSL-W and amphotericin-B on SAP gene expression.
Figure 4 Quantitative measurement of the reduced biofilm
formation with KSL-W. C. albicans was cultured on a 3D porous
scaffold in the presence of KSL-W for 2, 4, and 6 days. After each cul-
ture period, the samples were supplemented with XTT solution and
incubated for 5 h at 37°C. The absorbance at 450 nm was measured
to quantify XTT metabolic product intensity proportional to the
number of viable cells. (A) 2 days; (B) 4 days; (C) 6 days. Results are
means ± SD for three different separate experiments.
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3 h with KSL-W, but significantly (p < 0.001) decreased
after 6 h, while the expression of this gene was upregulated
(close to six folds) by amphotericin B (Tables 4 and 5).
Amphotericin B increased NRG1 mRNA expression almostthreefold, with no significant effect on the EFG1 gene, yet
significantly decreased HWP1 gene expression. On the
other hand, after 3 h (Table 4) and 6 h (Table 5) of incuba-
tion, KSL-W downregulated EFG1, NRG1, and HWP1
mRNA expression. Of interest is that except for similar
downregulatory effects on HWP1 gene expression, KSL-W
and amphotericin-B produced once again opposite results
regarding EFG1and NRG1 gene expression.
Discussion and conclusions
We demonstrated that KSL-W was effective in inhibiting
C. albicans growth at short and long culture periods. Al-
though growth inhibition obtained with KSL-W was less
than that obtained with amphotericin B, the effects of
KSL-W nevertheless remain significant (p < 0.01). The
growth inhibition effects of KSL-W are in accordance with
previously reported findings [37] showing a downregula-
tion of C. albicans activity induced by a bacteriocin-like
peptide isolated from Lactobacillus pentosus. Furthermore,
our results support other findings [38] reporting the ef-
fectiveness of KSL-W in disrupting P. gingivalis-induced
hemagglutination and its synergistic interaction with host
AMPs engaged in innate defense. The results strongly sug-
gest that KSL-W is also effective against fungal growth
and may be suitable for use to control C. albicans infec-
tions. Further studies on the possible synergistic effect of
amphotericin B and KSL-W against C. albicans growth
may provide insight.
C. albicans pathogenesis can also take place through
the transition from blastospore to hyphal form [39,40].
Our results indeed show that KSL-W completely inhib-
ited C. albicans transition with a concentration as low as
5 μg/ml. These data are consistent with those of other
studies with naturally occurring antimicrobial peptides
(e.g., β-defensins) which were effective in blocking the
morphological shift of Candida from yeast to hyphae
[41,42]. Thus KSL-W may possibly contribute to the
control of C. albicans infection by reducing cell growth
and yeast-hyphae transition. The effect of KSL-W on C.
albicans growth can occur either through cytolysis or
cell membrane disruption, resulting in cell death similar
to what has been demonstrated with histatin-5 [43,44].
Indeed, it was shown that histatin-5 induces the selective
leakage of intracellular ions and ATP from yeast cells.
This is caused by the translocation of histatin-5 into the
intracellular compartment and accumulates to a critical
concentration [45]. Further studies are thus warranted
to shed light on the fungicidal mechanism of KSL-W.
C. albicans growth and transition from blastospore to
hyphal form are particularly important for biofilm for-
mation and C. albicans virulence because a strain that is
genetically manipulated to grow exclusively in the yeast
form is greatly hindered in generating biofilms. In
addition, a variety of C. albicans mutants known to be
Figure 5 Biofilm ultrastructure following KSL-W treatment. C. albicans was cultured in Sabouraud medium without KSL-W for 6 days to
promote biofilm formation and maturation. The resulting biofilms were then treated or not with KSL-W or amphotericin B for 6 days, with
medium and peptide refreshing every 2 days. Following incubation, the samples were prepared as described in the Methods section and
observed under a scanning electron microscope.
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As KSL-W significantly reduced C. albicans growth and
inhibited its transition from yeast to hyphae, this sug-
gests that KSL-W may inhibit C. albicans biofilm forma-
tion. Our findings indicate that KSL-W was indeed able
to reduce biofilm formation and that its effect was com-
parable to that obtained with amphotericin B, a well-
known antifungal molecule. Also of interest is that a
significant inhibition of C. albicans biofilm formation
was obtained at a concentration of as low as 25 μg/ml of
KSL-W antimicrobial peptide. These useful data are
comparable to those of other studies showing the posi-
tive action of synthetic peptide in controlling and pre-
venting microbial biofilm formation [48]. Thus, with its
significant impact in reducing C. albicans biofilm forma-
tion, KSL-W may show potential for several novel appli-
cations in the clinical setting. Further investigations will
elucidate this effect.
Biofilm formation can be controlled with anti-biofilm
molecules prior to its development, although this is not
actually the case in clinical applications, as antifungal
and microbial molecules cannot be used on a daily basis
to prevent biofilm formation. An effective molecule
should ideally be able to prevent biofilm formation, but
more importantly to disrupt biofilms that are already
formed. We therefore questioned whether KSL-W was
capable of disrupting mature C. albicans biofilm.We proceeded to examine the impact of KSL-W on
mature biofilm formation and demonstrated a significant
disruption of these biofilms following contact with
KSL-W, thus suggesting the possible use of this antimicro-
bial peptide to reduce/eliminate mature biofilms. Further
studies should confirm such observations and demon-
strate how KSL-W reduces or disrupts C. albicans
biofilms.
Once it reaches the cell, KSL-W can potentially act on
the cytoplasmic membrane as well as on intracellular
targets [49-51]. The action of KSL-W against C. albicans
may operate through the modulated expression of cer-
tain C. albicans genes that control growth [52], transi-
tion [53], and biofilm formation [54]. We therefore
examined the effect of KSL-W on a number of genes ei-
ther directly or indirectly involved in phase transition
and biofilm formation. EFG1 and NRG1 expression was
assessed under hyphae/non-hyphae-inducing conditions.
Our results show that KSL-W increased NRG1 mRNA
expression twofold under non-hyphae-inducing condi-
tions; however, under hyphae-inducing conditions, KSL-
W significantly reduced NRG1 gene expression. These
findings contrast with other reports that an increased
NRG1 expression contributes to repressing various
hypha-specific genes [55,56]. This confirms that the ef-
fect of KSL-W in controlling C. albicans virulence does
not take place through NRG1. KSL-W was also able to
Figure 6 Decrease of biofilm mass following KSL-W treatment.
C. albicans was cultured in a 3D porous scaffold in Sabouraud
medium for 6 days to promote biofilm formation and maturation.
The resulting biofilms were exposed or not to KSL-W or amphotericin B
for 2, 4, and 6 days. Medium and peptide were refreshed every 2 days.
Following each treatment period, the samples were supplemented
with XTT solution and subsequently incubated for 5 h at 37°C.
Absorbance at 450 nm was measured to quantify XTT metabolic
product intensity proportional to the number of viable cells. (A) 2 days;
(B) 4 days; (C) 6 days. Results are means ± SD for three
separate experiments.
Table 2 Gene expression (6 h) under non-hyphae inducing cu
Gene Untreated C. albicans Amphotericin B
Fold change1 Fold change1 p-value2
SAP2 0.99 0.57 0.001
SAP4 0.96 0.19 <0.001
SAP5 1.00 0.08 <0.001
SAP6 1.00 0.05 <0.001
EAP1 1.00 4.91 0.028
HWP1 1.00 0.01 <0.001
1Fold change was calculated by PCR product of the gene of interest/the PCR produ
of untreated C. albicans where the expression was considered equal to 1.
2P-values were obtained after comparison of test to negative control (untreated C.
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maintained under hyphae-inducing conditions.
EFG1p has been found to be a central regulator of C. albi-
cans, as it is required for the development of a true hyphal
growth form, and EFG1 is considered to be essential in the
interactions between C. albicans and human host cells [7,8].
The downregulation of this gene by KSL-W points to the
singular role of this antifungal peptide. Thus the effect of
KSL-W on C. albicans transition can be manifested through
a repression of certain genes, such as EFG1 and NRG1.
KSL-W has a significant inhibitory effect on EAP1 mRNA
expression. As a member of the GPI-CWP family [5,57], de-
leting EAP1 can reduce the adhesion of C. albicans to differ-
ent surfaces. This suggests that treatment with KSL-W may
reduce EAP1 expression, which in turn may contribute to
reducing C. albicans adhesion and ultimately, biofilm forma-
tion and pathogenesis. KSL-W was also shown to reduce
HWP1 mRNA expression, particularly when C. albicans
was cultured under hyphae-inducing conditions.
HWP1 is a downstream component of the cAMP-
dependent PKA pathway and is positively regulated by
EFG1 [58]. The transcript level of HWP1 decreased with
the KSL-W treatment at low and high concentrations.
These data suggest that KSL-W indeed impacts the ac-
tivity of the cAMP–EFG1 pathway and leads to an alter-
ation of C. albicans growth and morphogenesis. Further
studies are therefore required to investigate the inva-
sion/virulence of KSL-W-treated C. albicans.
It is well known that Candida pathogenesis can be
established by virtue of Candida growth and yeast-to-
hyphae morphogenesis. Specific SAP genes were found
to be preferentially expressed by Candida hyphal forms
[10,15,59]. Because KSL-W downregulated C. albicans
growth and transition, this may have occurred through a
modulation of the SAP genes. Our findings confirm that
KSL-W is capable of decreasing SAP2, SAP4, SAP5, and
SAP6 mRNA expression in C. albicans which may lead
to reducing C. albicans virulence [60-62].
Our study thus establishes, for the first time, a clear
link between an antimicrobial peptide (KSL-W), hyphaelture conditions
KSL-W 25 μg/ml KSL-W 100 μg/ml
Fold change1 p-value2 Fold change1 p-value2
0.24 <0.001 0.11 <0.001
0.29 <0.001 0.14 <0.001
0.16 <0.001 0.06 <0.001
0.14 <0.001 0.04 <0.001
0.4 <0.001 0.29 <0.001
0.6 0.032 0.02 <0.001
ct of ACT1 (the house keeping gene), and normalized to the negative control
albicans).
Table 3 Gene expression (3 h) under non-hyphae inducing culture conditions
Gene Untreated C. albicans Amphotericin B KSL-W 25 μg/ml KSL-W 100 μg/ml
Fold change1 Fold change1 p-value2 Fold change1 p-value2 Fold change1 p-value2
EFG1 1.00 5.71 <0.001 2.76 <0.001 1.98 0.073
NRG1 1.00 10.99 <0.001 1.77 <0.001 1.4 0.086
1Fold change was calculated by PCR product of the gene of interest/the PCR product of ACT1 (the house keeping gene), and normalized to the negative control
of untreated C. albicans where the expression was considered equal to 1.
2P-values were obtained after comparison of test to negative control (untreated C. albicans).
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and 6. However, the precise interactions between these
SAPs and KSL-W during C. albicans pathogenesis re-
main unclear. Additional studies should focus on identi-
fying the role of SAP subfamilies involved in Candida
invasion as well as the role of KSL-W in controlling
Candida virulence/pathogenesis in conjunction with
host defenses. In conclusion, this study is the first to
demonstrate that synthetic antimicrobial peptide KSL-W
downregulates C. albicans growth and transition, result-
ing in a decrease in biofilm formation and a disruption
of mature biofilm. Also of interest is that these effects
may occur through the modulation of C. albicans genes
EFG1, NRG1, EAP1, HWP1, and SAPs. Overall results
clearly suggest the potential of KSL-W as an antifungal
molecule.
Methods
C. albicans
C. albicans strain ATCC-SC5314 was cultured for 24 h
on Sabouraud dextrose agar plates (Becton Dickinson,
Oakville, ON, Canada) at 30°C. For the C. albicans suspen-
sions, one colony was used to inoculate 10 ml of Sabouraud
liquid medium supplemented with 0.1% glucose at pH 5.6.
The cultures were grown overnight in a shaking water bath
for 18 h at 30°C. The yeast cells were then collected,
washed with phosphate-buffered saline (PBS), counted with
a haemocytometer, and adjusted to 107/ml prior to use.Table 4 Gene expression (3 h) under hyphae inducing culture
serum, with culture incubation at 37ºC)
Gene Untreated C. albicans Amphotericin B
Fold change1 Fold change1 p-value2
SAP2 0.99 3.36 0.003
SAP4 0.96 2.41 0.02
SAP5 1.00 0.49 0.0007
SAP6 1.00 2.56 0.01
EAP1 1.00 6.06 < 0.001
EFG1 1.00 1.09 0.6
NRG1 1.00 2.45 0.01
HWP1 1.00 0.0055 < 0.001
1Fold change was calculated by PCR product of the gene of interest/the PCR produ
of untreated C. albicans where the expression was considered equal to 1.
2P-values were obtained after comparison of test to negative control (untreated C.Antimicrobial peptides
KSL-W (KKVVFWVKFK-NH2) was synthesized by
standard solid-phase procedures [63] with 9-fluorenyl-
methoxycarbonyl (Fmoc) chemistry in an automatic pep-
tide synthesizer (model 90, Advanced ChemTech,
Louisville, KY, USA). The synthetic peptides were then
purified by reverse-phase HPLC (series 1100, Hewlett
Packard) by means of a Vydac C18 column. Peptide pur-
ity was confirmed by MALDI-TOF (matrix-assisted laser
desorption/ionization-time of flight) MS (AnaSpec Fre-
mont, CA, USA). The final product was stored in lyophi-
lized format -20°C until use. KSL-W solution was
prepared, filtered (0.22 um pore size), and used for the
experiments. Amphotericin B (Sigma-Aldrich, St. Louis,
MO, USA) was dissolved in distilled water to obtain a
250 μg/ml concentration which was also filtered, with
the sterile solution stored at -80°C until use.
Effect of KSL-W on C. albicans proliferation
Proliferation was investigated by placing 104 C. albicans
in 200 μL of Sabouraud dextrose broth in a round-
bottom 96-well plate. The C. albicans cultures were sup-
plemented with KSL-W at concentrations of 1, 10, 25,
50, 75, and 100 μg/ml. The negative controls were C.
albicans cultures not supplemented with KSL-W, while
the positive controls were C. albicans cultures supple-
mented with amphotericin B at concentrations of 1, 5,
and 10 μg/ml. The plates were incubated for 5, 10, andconditions (medium supplemented with 10% fetal calf
KSL-W 25 μg/ml KSL-W 100 μg/ml
Fold change1 p-value2 Fold change1 p-value2
0.78 0.02 0.62 0.003
0.44 0.0002 0.24 < 0.0001
0.83 0.03 0.01 < 0.0001
0.30 < 0.0001 0.11 < 0.0001
1.06 0.4 0.99 0.8
0.55 0.0004 0.66 0.02
0.66 0.0006 0.64 0.0005
0.078 < 0.0001 0.0035 < 0.0001
ct of ACT1 (the house keeping gene), and normalized to the negative control
albicans).
Table 5 Gene expression (6 h) under hyphae inducing culture conditions (medium supplemented with 10% fetal calf
serum, with culture incubation at 37ºC)
Gene Untreated C. albicans Amphotericin B KSL-W 25 μg/ml KSL-W 100 μg/ml
Fold change1 Fold change1 p-value2 Fold change1 p-value2 Fold change1 p-value2
SAP2 0.99 8.17 0.009 0.7 0.2 1.31 0.02
SAP4 0.96 2.58 0.03 0.73 0.04 0.72 0.04
SAP5 1.00 0.72 0.007 0.83 0.0004 0.56 0.006
SAP6 1.00 4.01 0.02 0.58 0.01 0.68 0.04
EAP1 1.00 6.36 0.001 0.44 0.008 0.73 0.003
EFG1 1.00 1.78 0.048 0.31 < 0.0001 0.47 0.01
NRG1 1.00 3.97 0.0005 0.37 0.001 0.37 0.05
HWP1 1.00 0.008 < 0.001 0.09 0.001 0.03 < 0.0001
1Fold change was calculated by PCR product of the gene of interest/the PCR product of ACT1 (the house keeping gene), and normalized to the negative control
of untreated C. albicans where the expression was considered equal to 1.
2P-values were obtained after comparison of test to negative control (untreated C. albicans).
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was assessed using the (3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyl tetrazolium bromide) MTT assay (Sigma-
Aldrich) which measures cell growth as a function of
mitochondrial activity [64]. Briefly, an MTT stock so-
lution (5 mg/ml) was prepared in PBS and added to
each culture at a final concentration of 10% (v/v). The
C. albicans cultures were then incubated with the
MTT solution at 30°C for 4 h, after which time the plate
was centrifuged for 10 min at 1200 rpm and the super-
natant was removed. The remaining pellet from each well
was then washed with warm PBS, with 200 μl of 0.04 N
HCl in isopropanol added to each well, followed by another
incubation for 15 min. Absorbance (optical density, OD)
was subsequently measured at 550 nm by means of an
xMark microplate spectrophotometer (Bio-Rad, Mississauga,
ON, Canada). Results are reported as means ± SD of three
separate experiments.
Effect of KSL-W on C. albicans transition from blastospore
to hyphal form
To determine the effect of KSL-W on the yeast-to-
hyphae transition, C. albicans (105 cells) was first grown
in 500 ml of Sabouraud dextrose broth supplemented
with 0.1% glucose and 10% fetal bovine serum (FBS).
KSL-W was then added (or not) to the culture at various
concentrations (1, 5, 10, 15, and 25 μg/ml). The negative
controls were the C. albicans cultures without anti-
microbial peptide, while the positive controls repre-
sented the C. albicans cultures supplemented with
amphotericin B (1, 5, and 10 μg/ml). The hyphae-
inducing conditions were previously reported [65], con-
sisting of culture medium supplementation with 10%
fetal calf serum and subsequent incubation at 37°C.
These conditions were used in our experiments. Follow-
ing incubation for 4 or 8 h, the cultures were observed
microscopically and photographed to record C. albicansmorphology (n = 5) and the density of C. albicans transi-
tion was measured.
Effect of KSL-W on C. albicans gene activation/repression
C. albicans was subcultured overnight in Sabouraud li-
quid medium supplemented with 0.1% glucose, pH 5.6,
in a shaking water bath for 18 h at 30°C. The yeast cells
were then collected, washed with PBS, and counted with
a hemocytometer, after which time they were co-
cultured with or without the antimicrobial peptide under
hyphae- or non-hyphae-inducing conditions, as follows.
Effect of KSL-W on gene activation when C. albicans was
cultured under non-hyphae-inducing conditions
C. albicans was co-cultured with either KSL-W (1, 25,
100 μg/ml) or amphotericin B (1 μg/ml) or with none of
these molecules (controls) in Sabouraud liquid medium
supplemented with 0.1% glucose, pH 5.6. The cultures
were maintained at 30°C for 3 and 6 h.
Effect of KSL-W on gene activation when C. albicans were
cultured under hyphae-inducing conditions
C. albicans was co-cultured with either KSL-W (1, 25,
100 μg/ml) or amphotericin B (1 μg/ml) or with none of
these molecules (controls) in Sabouraud liquid medium
supplemented with 0.1% glucose, pH 5.6. As previously
reported, to promote the transition of C. albicans from
blastospore to hyphal form, the culture medium was
supplemented with 10% fetal calf serum and the incuba-
tion was performed for 3 and 6 h at 37°C. Following
each culture period under both conditions [68], the cul-
tures were centrifuged 10 min at 13,000 rpm, the super-
natants were discarded, and each pellet was suspended
thereafter in 0.6 ml of lysis buffer (Glycerol 1 M, EDTA
0.1 M). Glass beads (0.425-0.6 mm in diameter; 0.2 ml)
were added to each suspended pellet prior to sonication
(4 × 1 min, followed by 2 min of incubation in ice) with
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USA). Following cell lysis, the total RNA was extracted
from each sample by means of the Illustra RNAspin Mini
kit (GE Health Care UK Limited, Buckingham, UK). Con-
centration, purity, and quality of the isolated RNA were
determined using the Experion system and RNA StdSens
analysis kit according to the instructions provided by the
manufacturer (Bio-Rad, Hercules, CA, USA).
Quantitative real-time RT-PCR
The RNA (500 ng of each sample) was reverse tran-
scribed into cDNA by means of the iScript cDNA Syn-
thesis kit (Bio-Rad, Mississauga, ON, Canada). The
conditions for the preparation of the cDNA templates
for PCR analysis were 5 min at 25°C, 1 h at 42°C, and
5 min at 85°C. Quantitative PCR (qPCR) was carried out
as previously described [36]. The quantity of mRNA
transcripts was measured with the Bio-Rad CFX96 real-
time PCR detection system. Reactions were performed
using a PCR supermix, also from Bio-Rad (iQ SYBR
Green supermix). Primers (Table 6) were added to the
reaction mix to a final concentration of 250 nM. Five
microliters of each cDNA sample were added to a 20 μl
PCR mixture containing 12.5 μl of the iQ SYBR Green
supermix, 0.5 μl of specific primers ACT1, SAP2, SAP4,
SAP5, SAP6, HWP1, and EAP1 (Midland Certified Re-
agent Company, Inc., Midland, TX, USA), as well asTable 6 Primer sequences used for the qRT-PCR
Gene Primer sequence 5′ to 3′ Amp size (bp)
ACT1 Forward : GCTGGTAGAGACTTGACCAACCA 87
Reverse : GACAATTTCTCTTTCAGCACTAGTAGTGA
SAP2 Forward : TCCTGATGTTAATGTTGATTGTCAAG 82
Reverse : TGGATCATATGTCCCCTTTTGTT
SAP4 Forward : AGATATTGAGCCCACAGAAATTCC 82
Reverse : CAATTTAACTGCAACAGGTCCTCTT
SAP5 Forward : CAGAATTTCCCGTCGATGAGA 78
Reverse : CATTGTGCAAAGTAACTGCAACAG
SAP6 Forward : TTACGCAAAAGGTAACTTGTATCAAGA 102
Reverse : CCTTTATGAGCACTAGTAGACCAAACG
ALS3 Forward : AATGGTCCTTATGAATCACCATCTACTA 51
Reverse : GAGTTTTCATCCATACTTGATTTCACAT
HWP1 Forward : GCTCAACTTATTGCTATCGCTTATTACA 67
Reverse : GACCGTCTACCTGTGGGACAGT
EAP1 Forward : CTGCTCACTCAACTTCAATTGTCG 51
Reverse : GAACACATCCACCTTCGGGA
EFG1 Forward : TATGCCCCAGCAAACAACTG 202
Reverse : TTGTTGTCCTGCTGTCTGTC
NRG1 Forward : CACCTCACTTGCAACCCC 198
Reverse : GCCCTGGAGATGGTCTGAEFG1 and NRG1 (Invitrogen Life Technologies Inc.,
Burlington, ON, Canada), and 7 μl of RNase/DNase-free
water (MP Biomedicals, Solon, OH, USA). Each reaction
was performed in a Bio-Rad MyCycler Thermal Cycler.
For the qPCR, the CT was automatically determined
using the accompanying Bio-Rad CFX Manager. The
thermocycling conditions for the ACT1, SAPs 2-4-5-6,
and EAP1 were established as 5 min at 95°C, followed
by 30 cycles of 15 s at 95°C, 30 s at 60°C, and 30 s at
72°C, with each reaction performed in triplicate. For the
EFG1 and NRG1, the thermocycling conditions were set
for 3 min at 95°C, followed by 45 cycles of 10 s at 95°C,
40 s at 54°C, and 40 s at 72°C, with each reaction also
performed in triplicate. For the HWP1, the conditions
were 3 min at 95°C, followed by 45 cycles of 10 s at
95°C, 30 s at 54°C, and 40 s at 72°C, with each reaction
performed in triplicate. The specificity of each primer
pair was determined by the presence of a single melting
temperature peak. The ACT1 produced uniform expres-
sion levels varying by less than 0.5 CTs between sample
conditions and thus became the reference gene for this
study. The results were analyzed by means of the 2−ΔΔCt
(Livak) relative expression method.
Effect of KSL-W on C. albicans biofilm formation
C. albicans biofilms were obtained by culturing the yeast
on a porous collagen scaffold which facilitated C. albicans
penetration through the pores and its adhesion to the
scaffold through collagen affinity. This also promoted
biofilm formation and handling with no cell loss, thus
contributing to maintaining the biofilm structure. For
this purpose, 5 mm × 5 mm samples of porous scaffold
(Collatape, Zimmer Dental Inc., Carlsbad, CA, USA)
were placed into a 24-well plate. The scaffolds were
then rinsed twice with culture medium, seeded with C.
albicans (105 cells), and incubated for 30 min at 30°C
without shaking to allow for adherence. Fresh Sabouraud
medium was added to each well in the presence or
absence of various concentrations of KSL-W (1, 10,
25, 50, 75, and 100 μg/ml). Two controls were included in
this study: the negative control was C. albicans seeded
without KSL-W, while the positive control was C. albicans
seeded with amphotericin B (1, 5, and 10 μg/ml). The C.
albicans-seeded scaffolds were then incubated for 2, 4,
and 6 days at 30°C. The medium, KSL-W, and ampho-
tericin B were refreshed every 48 h. Following each
culture period, C. albicans growth and biofilm forma-
tion was assessed by scanning electron microscopy and
XTT-menadione assay.
Scanning electron microscopy (SEM) analysis
Biofilms were fixed in ethylene glycol for 60 min and
rinsed once with sterile PBS. Dehydration was per-
formed in a series of 5-min treatments with ethanol
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twice at 100%). The dehydrated biofilms were kept over-
night in a vacuum oven at 25°C, after which time they
were sputter-coated with gold, examined, and imaged
(n = 4) under a JEOL 6360 LV SEM (Soquelec, Montréal,
QC, Canada) operating at a 30 kV accelerating voltage.
XTT reduction assay
To support the hypothesis that KSL-W quantitatively af-
fects C. albicans biofilms, an XTT reduction assay was
performed on the KSL-W-treated and control biofilms
at defined time points. XTT assay is one of the most
useful and accurate methods to investigate microbial
biofilm formation. The metabolic activity of the biofilm
cells was measured as a reflection of viable cell count.
To do so, C. albicans biofilms formed in the porous
scaffold with or without KSL-W treatments for 2, 4, and
6 days were subjected to an XTT assay. Fifty microliters
of XTT salt solution (1 mg/ml in PBS; Sigma-Aldrich)
and 4 μl of menadione solution (1 mM in acetone;
Sigma-Aldrich) were added to wells containing 4 ml of
sterile PBS. The biofilms were then added to the mixture
and the plates were incubated at 37°C for 5 h, after
which time the supernatant was collected to measure
the XTT formazan at 492 nm by means of an xMark mi-
croplate spectrophotometer (Bio-Rad, Mississauga, ON,
Canada).
Effect of KSL-W on the disruption of mature C. albicans
biofilms
Mature C. albicans biofilms were obtained by culturing
C. albicans (105) on a porous 3D collagen scaffold for
6 days at 30°C in Sabouraud liquid medium supple-
mented with 0.1% glucose at pH 5.6. The culture
medium was refreshed every 2 days. At the end of the 6-
day culture period, the biofilms were treated (or not)
with KSL-W (75 and 100 μg/ml). Amphotericin B-
treated biofilms (1, 5, and 10 μg/ml) were used as the
positive controls. The biofilms were continuously incu-
bated (or not) with either KSL-W or amphotericin B for
2, 4, and 6 days, with medium changing every day.
KSL-W and amphotericin B were also refreshed at each
medium changing. Following each incubation period,
SEM and XTT analyses were performed, as described
above.
Statistical analysis
Each experiment was performed at least four times, with
experimental values expressed as means ± SD. The stat-
istical significance of the differences between the control
(absence of KSL-W) and test (presence of KSL-W or
amphotericin B) values was determined by means of a
one-way ANOVA. Posteriori comparisons were per-
formed using Tukey’s method. Normality and varianceassumptions were verified using the Shapiro-Wilk test
and the Brown and Forsythe test, respectively. All of the
assumptions were fulfilled. P values were declared sig-
nificant at ≤ 0.05. The data were analyzed using the SAS
version 8.2 statistical package (SAS Institute Inc., Cary,
NC, USA).
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